What is Zacks Small Cap’s Estimate for PLX FY2025 Earnings?

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Analysts at Zacks Small Cap dropped their FY2025 EPS estimates for shares of Protalix BioTherapeutics in a report released on Tuesday, March 18th. Zacks Small Cap analyst J. Vandermosten now expects that the company will post earnings of $0.43 per share for the year, down from their prior estimate of $0.44. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share.

PLX has been the topic of a number of other reports. StockNews.com lowered Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday. HC Wainwright upped their price objective on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, February 3rd.

Protalix BioTherapeutics Stock Performance

NYSE PLX opened at $2.49 on Thursday. Protalix BioTherapeutics has a 1 year low of $0.82 and a 1 year high of $2.76. The business’s fifty day moving average is $2.40 and its two-hundred day moving average is $1.75. The stock has a market capitalization of $194.30 million, a P/E ratio of -19.15 and a beta of 0.72.

Institutional Trading of Protalix BioTherapeutics

Hedge funds have recently made changes to their positions in the stock. Squarepoint Ops LLC lifted its position in Protalix BioTherapeutics by 33.4% in the 4th quarter. Squarepoint Ops LLC now owns 73,940 shares of the company’s stock worth $139,000 after buying an additional 18,522 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. lifted its holdings in shares of Protalix BioTherapeutics by 13.7% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 53,507 shares of the company’s stock valued at $101,000 after buying an additional 6,434 shares during the last quarter. Millennium Management LLC grew its stake in shares of Protalix BioTherapeutics by 3.8% in the 4th quarter. Millennium Management LLC now owns 387,921 shares of the company’s stock valued at $729,000 after buying an additional 14,164 shares in the last quarter. Cubist Systematic Strategies LLC increased its holdings in Protalix BioTherapeutics by 24.1% in the fourth quarter. Cubist Systematic Strategies LLC now owns 29,307 shares of the company’s stock worth $55,000 after buying an additional 5,686 shares during the last quarter. Finally, Jane Street Group LLC grew its position in Protalix BioTherapeutics by 147.2% in the fourth quarter. Jane Street Group LLC now owns 113,616 shares of the company’s stock worth $214,000 after acquiring an additional 67,664 shares in the last quarter. 16.53% of the stock is owned by hedge funds and other institutional investors.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.